for malignant lymphoma and responded to ribavirin
Seiya Hashimoto1) , Hirofumi
Fukuda1) *, Kohei Takeda1),
Keiichi Uchida1), Fumiaki Sanuki2),
Takashi Akiyama2), Eisei Kondo1),
Hideho Wada1)
Department of Hematology, Kawasaki Medical School, Kurashiki,
Japan
Department of Pathology, Kawasaki Medical School, Kurashiki,
Japan
*Corresponding author
E-mail address: fukuda7@med.kawasaki-m.ac.jp (H. Fukuda).